ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

详细信息	查看全文 | 推荐本文 |

• 作者：Hee Kyung Ahn ; Boram Han ; Su Jin Lee ; Taekyu Lim ; Jong-Mu Sun ; Jin Seok Ahn ; Myung-Ju Ahn ; Keunchil Park ; ^{kpark@skku.edu}
• 关键词：ALK positive NSCLC ; ALK inhibitor ; Leptomeningeal carcinomatosis
• 刊名：Lung Cancer
• 出版年：2012
• 期刊代码：187_01695002
• 类别：med
• 出版时间：May, 2012
• 卷：76
• 期：2
• 页码：253-254
• 文件大小：115 K

摘要

Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.